What Is The Predicted Revenue Outlook For The Controlled Release Drug Delivery Market To Surpass $117.24 Billion?
Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
What CAGR And Valuation Are Anticipated For The Controlled Release Drug Delivery Market?
The market size of the controlled release drug delivery has experienced a swift expansion in the preceding years. It is anticipated to rise from $65.44 billion in 2024 to an impressive $72.34 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.5%. This historical period’s growth can be credited to the introduction of revolutionary drug delivery systems, preliminary polymer-based formulations, the start oft microencapsulation techniques, the rise of transdermal delivery, regulatory clearances, and standardization.
The market size for controlled release drug delivery is predicted to expand rapidly in the upcoming years, reaching a value of approximately $117.24 billion by 2029, with a compound annual growth rate (CAGR) of 12.8%. The key factors that are expected to contribute to this growth in the projected period include a move towards personalised medicine, the integration of technology for patient convenience, expansion in biologics and biosimilars, market growth in developing regions, and advancements in polymer science. The forecast period may also see emergence of several major trends, including biodegradable and biocompatible materials, advancements in nanotechnology, personalised and targeted therapies, improvements in implantable devices, and innovative encapsulation techniques.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9930&type=smp
What External And Internal Drivers Are Influencing The Controlled Release Drug Delivery Market?
The increasing occurrence of chronic diseases is anticipated to fuel the expansion of the controlled release drug delivery market. Chronic diseases, also referred to as noncommunicable diseases, include conditions, like heart disease, cancer, and diabetes, that persist for over a year and necessitate ongoing medical attention, restrict daily activities, or both. The treatment of chronic diseases is heavily reliant on controlled-release drug delivery. For chronically ill patients in need of long-term treatment or those living in areas with restricted resources and healthcare access, drug delivery methods that extend medication release are critical. For instance, a report from the World Health Organization (WHO), a health-specialized agency based in Switzerland, in September 2022 showed that every year, 41 million people succumb to chronic diseases, accounting for 74 percent of all global deaths. Furthermore, 17 million people die from chronic illnesses before they reach 70, with 77 percent of these deaths occurring in low- and middle-income countries. These statistics are predicted to increase in the future. Consequently, the escalating occurrence of chronic diseases is propelling the growth of the controlled release drug delivery market.
How Is The Controlled Release Drug Delivery Market Organized By Different Segments?
The controlled release drug delivery market covered in this report is segmented –
1) By Technology: Wurster Technique, Coacervation, Micro Encapsulation, Implants, Transdermal, Targeted Delivery, Other Technologies
2) By Release Mechanism: Polymer Based Systems, Micro Reservoir Partition Controlled Drug Delivery Systems, Feedback Regulated Drug Delivery Systems, Activation-Modulated Drug Delivery Systems, Chemically Activated,
3) By Application: Metered Dose Inhalers, Injectable, Transdermal And Ocular Patches, Other Applications
4) By End User: Hospitals, Clinics, Personal, Research, Other End Users
Subsegments:
1) By Wurster Technique: Spray Coating, Fluid Bed Coating
2) By Coacervation: Simple Coacervation, Complex Coacervation
3) By Micro Encapsulation: Polymer-Based Micro Encapsulation, Lipid-Based Micro Encapsulation
4) By Implants: Biodegradable Implants, Non-Biodegradable Implants
5) By Transdermal: Microneedle Patches, Reservoir Systems, Matrix Systems
6) By Targeted Delivery: Nanoparticles, Antibody-Drug Conjugates, Liposomes
7) By Other Technologies: Osmotic Pumps, In Situ Gelling Systems
What Current And Upcoming Trends Are Shaping The Controlled Release Drug Delivery Market?
The rise in technological advancements is an emerging trend observed in the controlled-release drug delivery market. To secure their market standing, major companies in this domain are adapting to innovative technologies. Take the example of Evonik Industries AG, a pharmaceutical firm based in Germany, which in March 2022, introduced UDRATEC SoluFlow, an innovative microparticle technology aimed at enhancing the solubility of active ingredients in oral drugs. This strategy using an emulsion-based process surpasses the limitations of conventional production procedures. EUDRATEC SoluFlow is the latest addition to Evonik Health Care’s selection of oral drug delivery system solutions, featuring oral excipients such as EUDRAGIT functional polymers, functional capsules like EUDRACAPTM ready for filling, and a range of other technologies and services crafted to improve the performance of medications.
Which Firms Are Making The Biggest Impact In The Controlled Release Drug Delivery Market?
Major companies operating in the controlled release drug delivery market include Johnson & Johnson Services Inc., Merck & Co. Inc., Alkermes plc, Coating Place Inc., Corium International Inc., Depomed Inc., Pfizer Inc., Aradigm Corporation, Capsugel LLC, GlaxoSmithKline plc, Bayer Healthcare LLC, Collegium Pharmaceuticals Inc., GE HealthCare Technologies Inc., Adare Pharmaceuticals Inc., Allergan plc, Novartis AG, Lonza Group AG, Colorcon Inc., SKY Pharmaceuticals Pvt. Ltd., AstraZeneca plc, Biogen Inc., Orbis Biosciences Inc., Alza Corporation, MicroCHIPS Inc., Endo International plc, Heron Therapeutics Inc., Intellipharmaceutics International Inc., Ipsen Biopharmaceuticals Inc., Luye Pharma Group Ltd., Medtronic plc, Nektar Therapeutics, Novo Nordisk A/S, Ocular Therapeutix Inc., Pacira BioSciences Inc., Progenity Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Titan Pharmaceuticals Inc., Vectura Group plc, West Pharmaceutical Services Inc., Zosano Pharma Corporation, Zynerba Pharmaceuticals Inc.
Access The Complete Report Here:
Which Region Dominates The Controlled Release Drug Delivery Market Today?
North America was the largest region in the controlled release drug delivery market in 2024. The regions covered in the controlled release drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=9930&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
